Darusentan (LU-135252; HMR-4005) is an
endothelin receptor antagonist.
Gilead Colorado, a subsidiary of
Gilead Sciences
Gilead Sciences, Inc. () is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and C ...
, under license from
Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled
hypertension.
In June 2003,
Myogen licensed the compound from Abbott for its application in the cancer field.
In May 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacy
phase III trial was initiated in subjects who had completed the maintenance period of the DAR-312 study, but was terminated because the study did not reach its primary endpoints.
See also
*
Ambrisentan
References
Endothelin receptor antagonists
Barbiturates
Experimental drugs
Lactims
Carboxylic acids
Diphenylmethanol ethers
Aromatic ethers
{{antineoplastic-drug-stub